Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Regulatory News (AMYT)

  • There is currently no data for AMYT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Completion of Foum Assaka Licence Farm-out

30 Apr 2014 07:00

RNS Number : 8418F
Fastnet Oil & Gas PLC
30 April 2014
 



Fastnet Oil & Gas PLC

 

 30 April 2014

  

Fastnet Oil & Gas Plc

Formal Completion of Farm-out of Foum Assaka Licence, offshore Morocco, to SK Innovation

 and Celtic Sea Operational Update

 

Foum Assaka Licence

 

Fastnet Oil & Gas Plc ("Fastnet") (AIM: FAST, ESM: FOI), the E&P company focused on exploration acreage in Africa and in the Celtic Sea, is pleased to announce formal completion of its farm-out of a 9.375% interest in the Foum Assaka Licence, off-shore Morocco, to SK Innovation, the energy and chemicals affiliate of SK Group, South Korea's third largest conglomerate. Completion had been previously subject to receipt of a Joint Ministerial Order from the Moroccan Authorities confirming the farm-out and approval for the farm-out transaction from the Korean Ministry of Trade, Industry and Energy.

 

Following the completion of the Transaction, SK Innovation is due to pay Fastnet accumulated back costs of US$20.4 million. Fastnet is also carried through its share of the drilling costs for the FA-1 well, which is currently ongoing, up to a gross well cost of $100m as well as either an appraisal well or, at SK Innovation's discretion, a further exploration well (also capped at USD$100m gross).

 

Fastnet holds its interest in the Foum Assaka licence area through its wholly owned subsidiary Pathfinder Hydrocarbon Ventures Limited. Following completion of the transaction, Fastnet will hold a 9.375% interest in the Foum Assaka Licence, with Kosmos Energy Deepwater Morocco, a subsidiary of Kosmos Energy Ltd. holding 29.925%, BP Plc 26.325%, SK Innovation 9.375% and ONHYM the remaining 25%.

 

Celtic Sea Operational Update

 

Initial interpretation of Fastnet's processed 3D seismic surveys acquired over Mizzen and Deep Kinsale in 2013 has identified 22 structures in the prospective Upper Jurassic to Lower Cretaceous interval. The largest structure underlies the Kinsale gas field and covers an area of 110 sq. km. Two large structures covering 45 and 63 sq. km. respectively have been identified in Mizzen, which also, importantly, contains four additional seismic amplitude-driven structural leads that are potential gas anomalies.

 

In addition to the structural leads, there are a number of potential stratigraphic traps in the Lower Cretaceous and further deep-seated structural leads in the Triassic and Jurassic, which 3D seismic acquisition has better defined relative to the historical legacy 2D seismic.

 

This 3D seismic data are being made available to potential farminees seeking material prospects and "running room".

Commenting, Paul Griffiths, Managing Director of Fastnet, said:

 

"We are pleased to have concluded the Foum Assaka farm-out and look forward to working with SK Innovation during the ongoing FA-1 drilling programme. The accumulated costs paid to Fastnet will further strengthen our balance sheet and allow us to prudently develop our business objectives during 2014 and 2015.

 

"The substantial investment in 3D seismic coverage, the largest in 45 years, in the Celtic Sea in 2013 is beginning to pay dividends as the results are proving to be a catalyst stimulating industry interest in our licence portfolio. This interest is reflected in the first-ever conference dedicated exclusively to the Celtic Sea business development and exploration opportunities being held in Dublin later today which is being attended by 20 global explorers from 4 continents."

 

Fastnet Oil & Gas plc

Cathal Friel, Chairman

Paul Griffiths, Managing Director

+353 (1) 644 0007

 

Shore Capital

Nomad

Bidhi Bhoma, Edward Mansfield

Corporate Broking

Jerry Keen

 

+44 (0) 20 7408 4090

 

GMP Securities Europe LLP

(Joint Broker)

Rob Collins

 

+44 (20) 20 7467 2800

 

Davy

(ESM Adviser & Joint Broker)

John Frain, Anthony Farrell

 

+353 (1) 679 6363

 

Bell Pottinger

Philip Dennis, Rollo Crichton-Stuart, James Lea

 

+44 (0) 207 861 3232

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCEAPLNASPLEFF
Date   Source Headline
6th Jan 20225:30 pmRNSAmryt Pharma
6th Jan 20227:00 amGNWKey Dates for AIM Delisting
4th Jan 202212:00 pmGNWThe Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients
4th Jan 20227:00 amGNWTotal Voting Rights
1st Dec 20217:00 amGNWTotal Voting Rights
30th Nov 20217:00 amGNWDirector/PDMR Shareholding
23rd Nov 202112:00 pmGNWAmryt Provides Update on Regulatory Review Process for Oleogel-S10
22nd Nov 20217:00 amGNWAmryt Announces the Cancellation of Admission of its Ordinary Shares to Trading on AIM
3rd Nov 202111:00 amGNWAmryt Reports Strong Q3 2021 Results
1st Nov 20211:00 pmGNWTotal Voting Rights
1st Nov 20217:00 amRNSAmryt Supports Acromegaly Awareness Day
22nd Oct 20217:00 amRNSAmryt Supports Global EB Awareness Week 2021
20th Oct 202112:00 pmGNWAmryt to Report Q3 2021 Results and Host Conference Call & Webcast on November 3
19th Oct 202112:00 pmGNWAmryt Announces New Patents for Oleogel-S10 and Mycapssa®
23rd Sep 202112:00 pmRNSAmryt Supports Global FH Awareness Day
13th Sep 202112:00 pmGNWAmryt Raises Full Year 2021 Revenue Guidance to $220M - $225M
1st Sep 20217:00 amGNWTotal Voting Rights
19th Aug 20217:00 amGNWAmryt Issues Ordinary Shares and Total Voting Rights
13th Aug 20211:23 pmRNSHolding(s) in Company - Replacement
11th Aug 202111:30 amRNSHoldings in Company
11th Aug 202110:36 amRNSHolding(s) in Company
10th Aug 20212:20 pmGNWDirector/PDMR Shareholding
10th Aug 20219:53 amRNSHolding(s) in Company
9th Aug 202112:00 pmGNWAmryt Virtual Capital Markets Event - September 13, 2021 – 1000-1200 EDT
6th Aug 202112:00 pmGNWAmryt Reports Record Q2 2021 Results and Raises FY 2021 Guidance
5th Aug 20213:50 pmGNWAmryt Successfully Completes Acquisition of Chiasma, Inc., Board Appointments, Issues Ordinary Shares and Total Voting Rights
28th Jul 20213:00 pmGNWResult of General Meetings
12th Jul 202112:00 pmGNWAmryt to Report Q2 2021 Results and Host Conference Call & Webcast on August 6
28th Jun 202112:00 pmGNWPublication of Circular to Amryt Shareholders in relation to the acquisition of Chiasma, Inc., and posting of Annual Report and Notices of General Meetings
15th Jun 202111:45 amGNWAmryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc.
7th Jun 202112:00 pmGNWFDA confirms NDA for Oleogel-S10 will not require an Advisory Committee Meeting
3rd Jun 20217:00 amGNWFDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
2nd Jun 20211:30 pmGNWAmryt Announces FDA Acceptance of New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
5th May 20214:41 pmRNSSecond Price Monitoring Extn
5th May 20214:35 pmRNSPrice Monitoring Extension
5th May 202112:05 pmGNWAmryt Reports Record Q1 2021 Financial and Operating Results
5th May 202112:00 pmGNWAmryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and Orphan Diseases
15th Apr 202112:00 pmGNWAmryt to Report Q1 2021 Results and Host Conference Call & Webcast on May 5
6th Apr 20217:00 amGNWAmryt Announces the Appointment of Sheila Frame as President Americas
31st Mar 202111:00 amRNSAmryt Supports World Lipodystrophy Day
31st Mar 20217:00 amGNWAmryt Submits a New Drug Application to the US Food and Drug Administration for Oleogel-S10* (Filsuvez®)
30th Mar 20217:00 amGNWAmryt Announces Results from an Investigator Sponsored Study of Lomitapide in FCS
29th Mar 20217:00 amGNWAmryt Announces Validation of its MAA by the EMA for Oleogel-S10* (Filsuvez®)
23rd Mar 20217:00 amGNWAmryt Receives Positive Feedback from the FDA on the Path Forward for Myalept® (metreleptin) Indication in Partial Lipodystrophy
22nd Mar 20217:00 amGNWAmryt Receives Reimbursement Approval from the French Ministry of Social Affairs and Health for Myalepta® (metreleptin)
15th Mar 202110:00 amGNWDirector/PDMR Shareholding
12th Mar 20217:00 amGNWExercise of Options and Total Voting Rights
11th Mar 202111:30 amGNWExercise of Warrants & Issue of Ordinary Shares and Total Voting Rights
8th Mar 20216:00 pmGNWDirector/PDMR Shareholding
8th Mar 20217:00 amGNWAmryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.